Cd33 Positive Microglia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CD33 (Siglec-3) is a sialic acid-binding immunoglobulin-like lectin expressed on microglia and other myeloid cells. CD33-positive microglia play a complex role in neurodegenerative diseases, particularly Alzheimer's disease, where genetic variants in CD33 have been associated with altered disease risk.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Cell Type Specificity: Primarily expressed on microglia in the brain
- Expression Levels: Variable expression across brain regions and disease states
- Alternative Splicing: Different isoforms with varying functional properties
The CD33 rs3865444 variant has been associated with:
- Reduced CD33 expression on microglia
- Decreased Alzheimer's disease risk
- Altered sialic acid binding properties
CD33-positive microglia influence amyloid-beta clearance through:
- Sialic Acid Binding: Recognition of sialylated targets
- Phagocytic Regulation: Modulation of phagocytic capacity
- Receptor Cross-talk: Interactions with other immune receptors
CD33 regulates microglial inflammatory responses:
- Inhibitory Signaling: CD33 contains immunoreceptor tyrosine-based inhibition motifs (ITIMs)
- Cytokine Production: Modulates production of pro-inflammatory cytokines
- Immune Activation: Regulates microglial activation states
- Anti-CD33 Antibodies: Immunotherapy approaches to modulate microglial function
- Small Molecule Inhibitors: Compounds targeting CD33 signaling pathways
- Gene Silencing: siRNA and antisense approaches
- CD33 risk variants influence treatment response
- CD33 expression serves as a biomarker
- Targeting CD33 may enhance microglial clearance functions
- Increased CD33 expression in AD brain tissue
- Association between CD33 variants and disease progression
- Correlation with amyloid burden in specific brain regions
- CD33 knockout mice show altered amyloid pathology
- Deficiency leads to enhanced microglial phagocytosis
- Modulates neuroinflammatory responses
The study of Cd33 Positive Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- CD33 genetic variants and Alzheimer's disease risk
- CD33 expression in Alzheimer's disease microglia
- Targeting CD33 for Alzheimer's disease therapy
- Microglial CD33 in amyloid clearance
- CD33 rs3865444 and functional outcomes in AD